Female Sexual Dysfunction Clinical Trial
Official title:
Investigation of Awareness Levels of Women Living in Turkey About Kegel Exercises and Pelvic Floor Muscles
Verified date | October 2023 |
Source | Istanbul Medipol University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Pelvic floor disorders affect millions of women and their lives in our country and around the world. Along with many factors such as age, obesity, menopause, smoking, number of births and mode of delivery, there is an increase in the prevalence of pelvic floor disorders. Pelvic floor disorders (urinary/fecal incontinence, pelvic organ prolapse, chronic pelvic pain, sexual dysfunction) negatively affect women, their families, caregivers of individuals who cannot meet their own needs, and society in many ways. Treatment of pelvic floor disorders is very costly on a community basis. An effective process is carried out with the use of non-pharmacological traditional and complementary therapies instead of invasive or pharmacological treatment in the early period of the treatment of symptoms of pelvic floor disorders.
Status | Completed |
Enrollment | 182 |
Est. completion date | October 13, 2023 |
Est. primary completion date | September 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Living in Turkey - Women aged 18 and over - Having an active sex life Exclusion Criteria: - Having a disease affecting the pelvic floor muscles - Having pelvic surgery in the last 6 months - Being receiving sexual therapy |
Country | Name | City | State |
---|---|---|---|
Turkey | HAZAL genç | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Istanbul Medipol University Hospital |
Turkey,
Khosravi A, Riazi H, Simbar M, Montazeri A. Effectiveness of Kegel exercise and lubricant gel for improving sexual function in menopausal women: A randomized trial. Eur J Obstet Gynecol Reprod Biol. 2022 Jul;274:106-112. doi: 10.1016/j.ejogrb.2022.05.022. Epub 2022 May 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Demographic Information: | It was used to measure the general knowledge of the participants and their knowledge of knowing and applying Kegel exercises.
Whether there is information about the pelvic floor muscles and Kegel exercises, the source of this information, whether the exercises are applied, which one is applied, the reason for the application, how long it is applied, whether the application is continued, from whom the training is received, how it is applied, whether it has positive effects. It is a questionable scale. |
one day | |
Primary | Female sexual function scale (FSFI) | The sexual functions of each subject included in the study were analyzed using the Female Sexual Function Index (FSFI). In the structure of the scale; There are 6 sub-dimensions: desire, arousal, lubrication (lubrication, wetting), orgasm, satisfaction and pain. Each item is scored from zero to 5. Accordingly, the highest raw score that can be obtained from the scale is 95.0 and the lowest raw score is 40. The reliability of the test was evaluated in two ways; Internal consistency and test-retest reliability were determined separately for 6 sub-dimensions with Cronbach's Alpha and their values were found to be 0.82 and higher. | one day | |
Primary | Sexual Life Quality Scale- Female: | Each item is expected to be answered by considering the sexual life in the last four weeks. In scoring the scale, each question is scored between 1 and 6. The range of points that can be obtained from the scale is between 18 and 108. The scores of items 1, 5, 9, 13 and 18 must be reversed before the total score can be calculated. In order to convert the total scale score to 100 (raw score-18 from the scale), the formula x100/90 should be used. A high score from the scale indicates that the quality of sexual life is good. | one day | |
Secondary | Beck Anxiety Scale | It is a self-report scale that determines the frequency of anxiety symptoms experienced by individuals. It is a Likert-type scale consisting of 21 items and scored between 0-3. The high scores obtained from the scale indicate the severity of the anxiety experienced by the individual. If the scores obtained from the scale are in the range of 0-7 points, it is considered as minimal anxiety / normal, between 8-15 points as mild anxiety, between 16-25 points as moderate anxiety, and between 26-63 points as severe anxiety. Although it is not certain, it is generally recommended to start medical treatment for individuals above 16 points. The treatment should be given by looking at the clinical condition of the patient as well as the score obtained from the scale. | one day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01364623 -
PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women
|
Phase 1 | |
Completed |
NCT06060691 -
the Ameliorating Effects of Antioxidant Gel on Female Arousal Disorder and Sexual Dysfunction
|
Phase 1 | |
Recruiting |
NCT04419961 -
Sexual Dysfunction and an Educational Program to Improve the Quality of Sexual Function in Vietnamese Pregnant Women in First Trimester
|
N/A | |
Completed |
NCT04122703 -
Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
|
N/A | |
Recruiting |
NCT03498443 -
Effect of Pelvic Organ Prolapse Surgeries on Female Sexual Function in Egyptian Women
|
||
Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
Completed |
NCT04124640 -
Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.
|
||
Completed |
NCT00995072 -
Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
|
N/A | |
Active, not recruiting |
NCT05168371 -
Cognitive-Behavioural & Mindfulness-Based Online Programs for Female Sexual Dysfunction
|
N/A | |
Completed |
NCT04384172 -
Effect of Peripheral Neuromodulation on Vaginal Blood Flow
|
N/A | |
Recruiting |
NCT06237166 -
Evaluation of an Online Intervention for Female Sexual Dysfunction
|
N/A | |
Completed |
NCT03463707 -
BP101 for Adults With Female Sexual Dysfunction
|
Phase 3 | |
Recruiting |
NCT01078077 -
The Impact of a Topical Vasodilating Cream on Female Sexual Experience
|
N/A | |
Completed |
NCT01724658 -
Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT02229721 -
Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00479570 -
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
|
Phase 2 | |
Not yet recruiting |
NCT06116045 -
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder
|
Phase 2 | |
Withdrawn |
NCT02862184 -
Female Sexual Dysfunction, Risks and Outcomes (FSFI)
|
N/A | |
Completed |
NCT01195701 -
Clitoral Location in Relation to Sexual Function Using Pelvic Imaging
|
N/A | |
Completed |
NCT04484753 -
Validation of iPelvis App for Female Pelvic Floor Dysfunction
|
N/A |